Resultados de procura - Jan Cools

Limitar resultados
  1. 1
    The genetics and molecular biology of T-ALL

    The genetics and molecular biology of T-ALL por Tiziana Girardi, Carmen Vicente, Jan Cools, Kim De Keersmaecker

    Publicado 2017
    Ligazón do recurso Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  2. 2
    The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11)

    The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11) por Bartosz Wasąg, Els Lierman, Mira Meeus, Jan Cools, Peter Vandenberghe

    Publicado 2011
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  3. 3
    Molecular Mechanisms Underlying FIP1L1-PDGFRA–Mediated Myeloproliferation

    Molecular Mechanisms Underlying FIP1L1-PDGFRA–Mediated Myeloproliferation por Miranda Buitenhuis, Liesbeth P. Verhagen, Jan Cools, Paul J. Coffer

    Publicado 2007
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  4. 4
    Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases

    Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases por Els Lierman, Sanne Smits, Jan Cools, Barbara Dewaele, Maria Dębiec‐Rychter, Peter Vandenberghe

    Publicado 2012
    Ligazón do recurso
    Carta
    Engadir a favoritos
    Gardado en:
  5. 5
    The ability of sorafenib to inhibit oncogenic PDGFR and FLT3 mutants and overcome resistance to other small molecule inhibitors

    The ability of sorafenib to inhibit oncogenic PDGFR and FLT3 mutants and overcome resistance to other small molecule inhibitors por Els Lierman, Idoya Lahortiga, Helen Van Miegroet, Nicole Mentens, Peter Marynen, Jan Cools

    Publicado 2007
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  6. 6
    The FIP1L1-PDGFRα fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management

    The FIP1L1-PDGFRα fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management por Jason Gotlib, Jan Cools, James Malone, Stanley L. Schrier, D. Gary Gilliland, Steven Coutré

    Publicado 2003
    Ligazón do recurso Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  7. 7
    The NPM-ALK and the ATIC-ALK Fusion Genes Can Be Detected in Non-Neoplastic Cells

    The NPM-ALK and the ATIC-ALK Fusion Genes Can Be Detected in Non-Neoplastic Cells por Brigitte Maes, Vera Vanhentenrijk, Iwona Włodarska, Jan Cools, Benjamin Peeters, Peter Marynen, Christiane De Wolf‐Peeters

    Publicado 2001
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  8. 8
    Mutation analysis of the tyrosine phosphatase PTPN2 in Hodgkin's lymphoma and T-cell non-Hodgkin's lymphoma

    Mutation analysis of the tyrosine phosphatase PTPN2 in Hodgkin's lymphoma and T-cell non-Hodgkin's lymphoma por M. Kleppe, Thomas Tousseyn, Eva Geissinger, Zeynep Kalender Atak, Stein Aerts, Andreas Rosenwald, Iwona Włodarska, Jan Cools

    Publicado 2011
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  9. 9
    Prediction of Resistance to Small Molecule FLT3 Inhibitors

    Prediction of Resistance to Small Molecule FLT3 Inhibitors por Jan Cools, Nicole Mentens, Pascal Furet, Doriano Fabbro, Jennifer Clark, James D. Griffin, Peter Marynen, D. Gary Gilliland

    Publicado 2004
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  10. 10
    Evidence for position effects as a variantETV6-mediated leukemogenic mechanism in myeloid leukemias with a t(4;12)(q11-q12;p13) or t(5;12)(q31;p13)

    Evidence for position effects as a variantETV6-mediated leukemogenic mechanism in myeloid leukemias with a t(4;12)(q11-q12;p13) or t(5;12)(q31;p13) por Jan Cools, Nicole Mentens, María D. Odero, Pieter J. Peeters, Iwona Włodarska, Michel Delforge, Anne Hagemeijer, Peter Marynen

    Publicado 2002
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  11. 11
    Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518

    Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518 por Jennifer Clark, Jan Cools, David P. Curley, Jin‐Chen Yu, Nathalie A. Lokker, Neill A. Giese, D. Gary Gilliland

    Publicado 2004
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  12. 12
    Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness

    Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor progno... por Amy D. Klion, Pierre Noël, Cem Akin, Melissa Law, D. Gary Gilliland, Jan Cools, Dean D. Metcalfe, Thomas B. Nutman

    Publicado 2003
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  13. 13
    The Long Non-coding RNA Flatr Anticipates Foxp3 Expression in Regulatory T Cells

    The Long Non-coding RNA Flatr Anticipates Foxp3 Expression in Regulatory T Cells por Aleksandra Brajic, Dean Franckaert, Oliver T. Burton, Simon Bornschein, A. Calvanese, Sofie Demeyer, Jan Cools, James Dooley, Susan Schlenner, Adrian Liston

    Publicado 2018
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  14. 14
    Activity of Dasatinib, a Dual SRC/ABL Kinase Inhibitor, and IPI-504, a Heat Shock Protein 90 Inhibitor, against Gastrointestinal Stromal Tumor–Associated PDGFRAD842V Mutation

    Activity of Dasatinib, a Dual SRC/ABL Kinase Inhibitor, and IPI-504, a Heat Shock Protein 90 Inhibitor, against Gastrointestinal Stromal Tumor–Associated PDGFRAD842V Mutation por Barbara Dewaele, Bartosz Wasąg, Jan Cools, Raf Sciot, Hans Prenen, Peter Vandenberghe, Agnieszka Woźniak, Patrick Schöffski, Peter Marynen, Maria Dębiec‐Rychter

    Publicado 2008
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  15. 15
    Sorafenib is a potent inhibitor of FIP1L1-PDGFRα and the imatinib-resistant FIP1L1-PDGFRα T674I mutant

    Sorafenib is a potent inhibitor of FIP1L1-PDGFRα and the imatinib-resistant FIP1L1-PDGFRα T674I mutant por Els Lierman, Cedric Folens, Elizabeth H. Stover, Nicole Mentens, Helen Van Miegroet, Werner Scheers, Marc Boogaerts, Peter Vandenberghe, Peter Marynen, Jan Cools

    Publicado 2006
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  16. 16
    Targeting PIM Kinases Impairs Survival of Hematopoietic Cells Transformed by Kinase Inhibitor–Sensitive and Kinase Inhibitor–Resistant Forms of Fms-Like Tyrosine Kinase 3 and BCR/ABL

    Targeting PIM Kinases Impairs Survival of Hematopoietic Cells Transformed by Kinase Inhibitor–Sensitive and Kinase Inhibitor–Resistant Forms of Fms-Like Tyrosine Kinase 3 and BCR/A... por Myriam Adam, Vanda Pogac̆ić, Marina Bendit, Richard Chappuis, Martijn C. Nawijn, Justus Duyster, Casey Fox, Craig B. Thompson, Jan Cools, Juerg Schwaller

    Publicado 2006
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  17. 17
    Activation of FIP1L1-PDGFRα requires disruption of the juxtamembrane domain of PDGFRα and is FIP1L1-independent

    Activation of FIP1L1-PDGFRα requires disruption of the juxtamembrane domain of PDGFRα and is FIP1L1-independent por Elizabeth H. Stover, Jing Chen, Cedric Folens, Benjamin H. Lee, Nicole Mentens, Peter Marynen, Ifor R. Williams, D. Gary Gilliland, Jan Cools

    Publicado 2006
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  18. 18
    In vitro validation of -secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia

    In vitro validation of -secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia por Kim De Keersmaecker, Idoya Lahortiga, Nicole Mentens, Cedric Folens, Leander Van Neste, Sofie Bekaert, Peter Vandenberghe, María D. Odero, Peter Marynen, Jan Cools

    Publicado 2008
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  19. 19
    ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions

    ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions por Katrien Van Roosbroeck, Jan Cools, Daan Dierickx, José Thomas, Peter Vandenberghe, Michel Stul, Jan Delabie, Chris De Wolf‐Peeters, Peter Marynen, Iwona Włodarska

    Publicado 2010
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  20. 20
    Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32)

    Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32) por Kim De Keersmaecker, Carlos Graux, María D. Odero, Nicole Mentens, Riet Somers, Johan Maertens, Iwona Włodarska, Peter Vandenberghe, Anne Hagemeijer, Peter Marynen, Jan Cools

    Publicado 2005
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:

Ferramentas de procura: